SV2A and Cognitive impairment: Treatments targeting synaptic dysfunction via synaptic vesicle glycoprotein 2A (SV2A) modulators such as ABBV-552 and AGB101, are in the phase I–III clinical trials for AD and for mild cognitive impairment (MCI) due to AD [14, 15].